1.7900
+0.0200
+(1.13%)
At close: April 17 at 4:00:01 PM EDT
1.8300
+0.04
+(2.23%)
After hours: April 17 at 7:54:45 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 4 |
| Avg. Estimate | -0.17 | -0.16 | -0.61 | -0.54 |
| Low Estimate | -0.19 | -0.18 | -0.69 | -0.61 |
| High Estimate | -0.15 | -0.14 | -0.53 | -0.47 |
| Year Ago EPS | -0.19 | -0.13 | -0.61 | -0.61 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 7 |
| Avg. Estimate | 4.49M | 5.05M | 23.03M | 32.13M |
| Low Estimate | 2.14M | 2.24M | 20.52M | 25.8M |
| High Estimate | 5.55M | 6.81M | 25.41M | 45.78M |
| Year Ago Sales | 3.8M | 7.61M | 26.39M | 23.03M |
| Sales Growth (year/est) | 18.09% | -33.62% | -12.73% | 39.48% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.16 | -0.17 | -0.14 | -0.1 |
| EPS Actual | -0.19 | -0.13 | -0.16 | -0.12 |
| Difference | -0.03 | 0.04 | -0.02 | -0.02 |
| Surprise % | -16.33% | 25.00% | -17.07% | -24.13% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.17 | -0.16 | -0.61 | -0.54 |
| 7 Days Ago | -0.17 | -0.16 | -0.61 | -0.54 |
| 30 Days Ago | -0.15 | -0.14 | -0.44 | -0.29 |
| 60 Days Ago | -0.15 | -0.14 | -0.44 | -0.29 |
| 90 Days Ago | -0.15 | -0.14 | -0.44 | -0.29 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | 2 |
| Down Last 30 Days | 1 | 2 | 5 | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| OABI | 12.28% | -20.52% | 0.82% | 11.57% |
| S&P 500 | 7.04% | 4.85% | 8.57% | 14.16% |
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 3/27/2025 |
| Maintains | Benchmark: Buy to Buy | 3/20/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/19/2025 |
| Reiterates | Benchmark: Buy to Buy | 11/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2024 |
| Reiterates | Benchmark: Buy to Buy | 8/19/2024 |
Related Tickers
LGND Ligand Pharmaceuticals Incorporated
104.97
+0.33%
UPB Upstream Bio, Inc.
8.78
+4.28%
SLRN Acelyrin, Inc.
2.2000
0.00%
OBIO Orchestra BioMed Holdings, Inc.
2.8500
-0.35%
ZURA Zura Bio Limited
1.2300
+6.96%
OCTHF Oxford Cannabinoid Technologies Holdings Plc
0.0028
0.00%
FNAM Evolutionary Genomics, Inc.
0.0002
0.00%
RDTCF Rapid Dose Therapeutics Corp.
0.0080
0.00%
BXPHF Botanix Pharmaceuticals Limited
0.2300
0.00%
A71.F Ascendis Pharma A/S
140.00
+6.06%